

02-10-03

1645

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098495674US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: February 7, 2003

Signature: Staci Harris

(Staci Harris)

Docket No.: HO-P02188US0  
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Goran Forsberg, et al

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: NOVEL ENGINEERED SUPERANTIGEN FOR  
HUMAN THERAPY

Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL LETTER**

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

1. Response to Restriction Requirement
2. Return Post Card

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: February 7, 2003

Respectfully submitted,

By Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT &amp; JAWORSKI L.L.P.


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

RECEIVED  
FEB 12 2003  
TECH CENTER 1600/2900



I hereby certify that this correspondence was deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098495674US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: February 7, 2003

Signature: *Staci Harris*

(Staci Harris)

*Election / #10*  
*2.26.03*  
Docket No.: HO-P02188US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Goran Forsberg, et al

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: NOVEL ENGINEERED SUPERANTIGEN FOR  
HUMAN THERAPY

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed January 14, 2003 (Paper No. 9), Applicants hereby provisionally elect Group III, claims 15-34 and 53-72 for continued examination on their merits without traverse.

The Examiner has also required a species election for Group III. In response to the species election, Applicants hereby provisionally elect the following species: SEE (Staphylococcal enterotoxin) for the antigen, 5T4 for the Fab fragment, lung cancer for the cancer, and IL-2 for the cytokine. Yet further, if SEE is elected, the Examiner has required specific substitutions to be elected. Thus, in response to the specific substitutions of position C and A, Applicants provisionally elect position C substitution 83 and position A substitution 27 to be prosecuted on their merits.

Applicants believe no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: February 7, 2003

Respectfully submitted,

By *Melissa W. Acosta*

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

RECEIVED  
FEB 12 2003  
TECH CENTER 1600/2900